Seo, Hong-Seog

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3,163

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 638

Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index

Hong, S. J., Park, C. G., Seo, H. S., Oh, D. J., & Ro, Y. M. (2004) · Blood Pressure

Cardiovascular Function and Risk FactorsCardiovascular Disease and Adiposity

Cited by 121

Effects of estrogen receptor α and β on the expression of visfatin and retinol-binding protein 4 in 3T3-L1 adipocytes

JUNG, U. S., JEONG, K. J., KANG, J. K., YI, K., SHIN, J.-H., SEO, H. S., KIM, T., KIM, S.-H., & HUR, J.-Y. (2013) · International Journal of Molecular Medicine

Estrogen and related hormone effectsAdipokines, Inflammation, and Metabolic Diseases

Cited by 15